vs

Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and CuriosityStream Inc. (CURI). Click either name above to swap in a different company.

AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $19.2M, roughly 1.0× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -541.1%, a 521.4% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 26.5%).

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

AGIO vs CURI — Head-to-Head

Bigger by revenue
AGIO
AGIO
1.0× larger
AGIO
$20.0M
$19.2M
CURI
Growing faster (revenue YoY)
AGIO
AGIO
+50.3% gap
AGIO
86.1%
35.8%
CURI
Higher net margin
CURI
CURI
521.4% more per $
CURI
-19.7%
-541.1%
AGIO
More free cash flow
CURI
CURI
$101.3M more FCF
CURI
$3.9M
$-97.3M
AGIO
Faster 2-yr revenue CAGR
AGIO
AGIO
Annualised
AGIO
56.1%
26.5%
CURI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGIO
AGIO
CURI
CURI
Revenue
$20.0M
$19.2M
Net Profit
$-108.0M
$-3.8M
Gross Margin
90.6%
Operating Margin
-608.9%
-17.6%
Net Margin
-541.1%
-19.7%
Revenue YoY
86.1%
35.8%
Net Profit YoY
-11.9%
-34.6%
EPS (diluted)
$-1.86
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGIO
AGIO
CURI
CURI
Q4 25
$20.0M
$19.2M
Q3 25
$12.9M
$18.4M
Q2 25
$12.5M
$19.0M
Q1 25
$8.7M
$15.1M
Q4 24
$10.7M
$14.1M
Q3 24
$9.0M
$12.6M
Q2 24
$8.6M
$12.4M
Q1 24
$8.2M
$12.0M
Net Profit
AGIO
AGIO
CURI
CURI
Q4 25
$-108.0M
$-3.8M
Q3 25
$-103.4M
$-3.7M
Q2 25
$-112.0M
$784.0K
Q1 25
$-89.3M
$319.0K
Q4 24
$-96.5M
$-2.8M
Q3 24
$947.9M
$-3.1M
Q2 24
$-96.1M
$-2.0M
Q1 24
$-81.5M
$-5.0M
Gross Margin
AGIO
AGIO
CURI
CURI
Q4 25
90.6%
Q3 25
87.0%
Q2 25
86.3%
Q1 25
87.6%
Q4 24
88.3%
Q3 24
91.3%
Q2 24
82.6%
Q1 24
92.3%
Operating Margin
AGIO
AGIO
CURI
CURI
Q4 25
-608.9%
-17.6%
Q3 25
-907.4%
-24.5%
Q2 25
-1020.1%
2.5%
Q1 25
-1222.0%
0.5%
Q4 24
-1165.3%
-27.4%
Q3 24
-1146.9%
-25.8%
Q2 24
-1228.3%
-20.6%
Q1 24
-1124.3%
-30.4%
Net Margin
AGIO
AGIO
CURI
CURI
Q4 25
-541.1%
-19.7%
Q3 25
-803.1%
-20.4%
Q2 25
-899.4%
4.1%
Q1 25
-1023.3%
2.1%
Q4 24
-899.6%
-19.9%
Q3 24
10574.7%
-24.3%
Q2 24
-1115.7%
-16.4%
Q1 24
-995.8%
-42.0%
EPS (diluted)
AGIO
AGIO
CURI
CURI
Q4 25
$-1.86
$-0.07
Q3 25
$-1.78
$-0.06
Q2 25
$-1.93
$0.01
Q1 25
$-1.55
$0.01
Q4 24
$-1.44
$-0.05
Q3 24
$16.22
$-0.06
Q2 24
$-1.69
$-0.04
Q1 24
$-1.45
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGIO
AGIO
CURI
CURI
Cash + ST InvestmentsLiquidity on hand
$89.1M
$27.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.2B
$41.5M
Total Assets
$1.3B
$75.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGIO
AGIO
CURI
CURI
Q4 25
$89.1M
$27.3M
Q3 25
$92.7M
$27.8M
Q2 25
$80.9M
$28.1M
Q1 25
$79.0M
$33.4M
Q4 24
$76.2M
$32.1M
Q3 24
$253.7M
$33.2M
Q2 24
$84.5M
$39.5M
Q1 24
$118.8M
$38.8M
Stockholders' Equity
AGIO
AGIO
CURI
CURI
Q4 25
$1.2B
$41.5M
Q3 25
$1.3B
$47.2M
Q2 25
$1.4B
$49.8M
Q1 25
$1.5B
$58.1M
Q4 24
$1.5B
$57.8M
Q3 24
$1.6B
$62.2M
Q2 24
$660.5M
$64.8M
Q1 24
$743.9M
$67.0M
Total Assets
AGIO
AGIO
CURI
CURI
Q4 25
$1.3B
$75.7M
Q3 25
$1.4B
$74.7M
Q2 25
$1.5B
$78.7M
Q1 25
$1.6B
$85.3M
Q4 24
$1.7B
$86.2M
Q3 24
$1.8B
$87.6M
Q2 24
$773.1M
$90.9M
Q1 24
$849.7M
$94.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGIO
AGIO
CURI
CURI
Operating Cash FlowLast quarter
$-96.2M
$4.0M
Free Cash FlowOCF − Capex
$-97.3M
$3.9M
FCF MarginFCF / Revenue
-487.5%
20.5%
Capex IntensityCapex / Revenue
5.6%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-377.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGIO
AGIO
CURI
CURI
Q4 25
$-96.2M
$4.0M
Q3 25
$-88.2M
$4.4M
Q2 25
$-77.1M
$2.8M
Q1 25
$-111.5M
$1.9M
Q4 24
$-133.2M
$3.0M
Q3 24
$-84.2M
$2.3M
Q2 24
$-72.6M
$2.2M
Q1 24
$-99.9M
$666.0K
Free Cash Flow
AGIO
AGIO
CURI
CURI
Q4 25
$-97.3M
$3.9M
Q3 25
$-89.7M
Q2 25
$-78.0M
Q1 25
$-112.3M
$1.8M
Q4 24
$-134.1M
Q3 24
$-84.6M
Q2 24
$-72.7M
Q1 24
$-100.0M
FCF Margin
AGIO
AGIO
CURI
CURI
Q4 25
-487.5%
20.5%
Q3 25
-696.5%
Q2 25
-626.2%
Q1 25
-1286.4%
12.2%
Q4 24
-1250.1%
Q3 24
-944.2%
Q2 24
-844.4%
Q1 24
-1221.2%
Capex Intensity
AGIO
AGIO
CURI
CURI
Q4 25
5.6%
0.1%
Q3 25
12.1%
0.0%
Q2 25
7.0%
0.0%
Q1 25
8.8%
0.5%
Q4 24
9.0%
0.0%
Q3 24
4.7%
0.0%
Q2 24
1.8%
0.0%
Q1 24
1.7%
0.0%
Cash Conversion
AGIO
AGIO
CURI
CURI
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
-0.09×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons